| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
J14 (0-100 μM; 0-96 hours; A549 cells) treatment inhibits A549 cell growth in a concentration- and time-dependent manner; 15.7 μM is the half-inhibitory concentration [1]. Treatment (48–72 hours; A549 cells) activates caspase-3 and caspase-9 in addition to releasing cytochrome c into the cytoplasm. J14 causes mitochondrial oxidative damage, which triggers caspase-mediated cell sanitization [1]. Intracellular ROS accumulation and sulfinate peroxidase were both markedly elevated by J14 treatment. When intracellular ROS build up excessively, oxidative damage results, ultimately leading to cell death. J14 significantly and time-pullingly promotes cell death in A549 cells, with around 40% of the cells dying in 96 hours [1]. Insulation of cells and J14 sensor short circuit damage [1]. Cells
|
|---|---|
| ln Vivo |
J14 (50 mg/kg; i.p.; daily; for 16 days; BALB/c female nude mice) therapy significantly reduced mean tumor volume. Compared with the control experiment, the main tumor mass of the J14 treatment experiment
|
| Cell Assay |
Cell Viability Assay [1] Cells
Cell Types: A549 Cell Tested Concentrations: 0-100 μM Incubation Duration: 0 hrs (hours), 24 hrs (hours), 48 hrs (hours), 72 hrs (hours), 96 hrs (hours) Experimental Results: Inhibited the growth of A549 cells in a concentration- and time-dependent manner. Western Blot Analysis [1] Cell Types: A549 cells Tested Concentrations: 20 μM Incubation Duration: 48 hrs (hours), 72 hrs (hours) Experimental Results: Not only caused the release of cytochrome c into the cytoplasm, but also caused the activation of caspase-3 and caspase-9. |
| Animal Protocol |
Animal/Disease Models: Sixweeks old BALB/c female nude mice injected with A549 cells [1]
Doses: 50 mg/kg Route of Administration: intraperitoneal (ip) injection; and weight were Dramatically reduce[1]. Routine; 16-day Experimental Results: Significant reduction in human lung tumor growth with no acute toxicity. |
| References |
| Molecular Formula |
C28H25CLN4O2S
|
|---|---|
| Molecular Weight |
517.0417
|
| Exact Mass |
516.138
|
| CAS # |
1043854-13-2
|
| PubChem CID |
45987688
|
| Appearance |
White to off-white solid powder
|
| LogP |
6.4
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
36
|
| Complexity |
695
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1=C([H])C([H])=C([H])C([H])=C1N1C([H])([H])C([H])([H])N(C2C([H])=C(C3C([H])=C([H])C([H])=C([H])C=3[H])N=C(N=2)SC([H])([H])C2C([H])=C([H])C(C(=O)O[H])=C([H])C=2[H])C([H])([H])C1([H])[H]
|
| InChi Key |
RSHUJZXWKLIBRE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C28H25ClN4O2S/c29-23-8-4-5-9-25(23)32-14-16-33(17-15-32)26-18-24(21-6-2-1-3-7-21)30-28(31-26)36-19-20-10-12-22(13-11-20)27(34)35/h1-13,18H,14-17,19H2,(H,34,35)
|
| Chemical Name |
4-[[4-[4-(2-chlorophenyl)piperazin-1-yl]-6-phenylpyrimidin-2-yl]sulfanylmethyl]benzoic acid
|
| Synonyms |
J14; J-14
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 125 mg/mL (~241.76 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.17 mg/mL (4.20 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 21.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.17 mg/mL (4.20 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 21.7 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9341 mL | 9.6704 mL | 19.3409 mL | |
| 5 mM | 0.3868 mL | 1.9341 mL | 3.8682 mL | |
| 10 mM | 0.1934 mL | 0.9670 mL | 1.9341 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
